Rituximab in relapsed/refractory antineutrophil cytoplasmic antibody associated vasculitis: A single-center prospective observational study
Background: Induction with cyclophosphamide (CYC) and glucocorticoids in antineutrophil cytoplasmic antibody-associated vasculitis (AAV) has a relapse of 30%–50%. Studies show that rituximab (RTX) is superior to CYC in refractory/relapsed AAV. We prospectively analyzed efficacy and safety of RTX in...
Saved in:
Main Authors: | Ekbote Gayatri, Tanna Dhaval, Negalur Natasha, Bindroo Muzaffar, Raval Dhiren, Sharma Lucky, Rajiva Gupta |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2019-01-01
|
Series: | Indian Journal of Rheumatology |
Subjects: | |
Online Access: | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2019;volume=14;issue=1;spage=12;epage=16;aulast=Gayatri |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical profile and outcome of antineutrophil cytoplasmic antibody-associated vasculitis: A retrospective observational study from South India
by: Sham Santhanam, et al.
Published: (2022-01-01) -
Anti-neutrophil cytoplasmic autoantibodies associated vasculitis – Clinical profile and outcomes
by: Kavya Devi Nunna, et al.
Published: (2018-01-01) -
Cost-minimization analysis of individually tailored or fixed-scheduled rituximab maintenance therapy for antineutrophil-cytoplasm antibody associated vasculitides
by: Ana Belén Guisado-Gil, et al.
Published: (2020-03-01) -
Antineutrophil cytoplasmic antibody-associated vasculitis in a patient with diffuse scleroderma
by: B N Shiva Prasad, et al.
Published: (2021-01-01) -
Efficacy and safety of avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis: a retrospective cohort study in Japan
by: Genri Tagami, et al.
Published: (2025-01-01)